CARDIAC INVOLVEMENT IN LIVER AND BILIARY TRACT DISEASES

View at publisher Summarise with VIRAT
Authors: Şule Arıcı
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cardiac involvement in pediatric liver and biliary tract diseases represents a complex and clinically significant field that is increasingly recognized in daily practice. The liver and heart are developmentally, metabolically, and hemodynamically interconnected, and pediatric disorders affecting one organ frequently have implications for the other. Unlike adults, where alcohol-related cirrhosis and nonalcoholic fatty liver disease dominate, the pediatric spectrum includes biliary atresia, Alagille syndrome, congenital hepatic fibrosis, metabolic hepatopathies, and autoimmune or infectious causes. These conditions lead to a wide range of cardiovascular consequences, from subclinical diastolic dysfunction to overt cardiomyopathy and pulmonary vascular complications. Several mechanisms contribute to cardiac injury in children with liver disease. Hemodynamic alterations related to portal hypertension cause chronic hyperdynamic circulation and myocardial remodeling. Bile acid toxicity and mitochondrial dysfunction impair contractility and promote arrhythmogenesis, while systemic inflammation drives myocardial remodeling and diastolic impairment. Endothelial dysfunction links liver disease to hepatopulmonary syndrome and portopulmonary hypertension, both of which carry serious prognostic implications. In addition, genetic and developmental syndromes such as Alagille syndrome and fibrocystic liver diseases demonstrate shared embryological pathways affecting both organs. Nutritional deficiencies, metabolic derangements, and rare conditions including Wilson disease, alpha-1 antitrypsin deficiency, and erythropoietic protoporphyria further contribute to cardiovascular vulnerability. Infectious agents may cause direct myocardial injury or indirectly promote dysfunction via systemic inflammation and portal hypertension. Clinical manifestations are often subclinical until stress situations such as liver transplantation, when preexisting cardiac abnormalities significantly affect perioperative outcomes. Diagnostic evaluation should therefore be systematic, incorporating clinical assessment, electrocardiography, echocardiography with tissue Doppler and strain imaging, biomarkers, and, when needed, advanced imaging or invasive hemodynamic studies. Management remains largely supportive, with careful attention to electrolyte balance, arrhythmia control, and pulmonary vascular complications. Liver transplantation is the only definitive treatment for several complications, though post-transplant surveillance remains essential due to persistent or de novo cardiac effects. In conclusion, cardiac involvement should be considered an integral component of pediatric liver and biliary tract diseases. Early recognition, multidisciplinary evaluation, and structured follow-up are crucial to improving survival, optimizing transplant outcomes, and enhancing quality of life. Future research focusing on advanced imaging, biomarkers, and multicenter pediatric cohorts will help refine screening strategies and therapeutic approaches in this vulnerable population.Keywords: Liver diseases; Biliary tract diseases; Cardiomyopathies; Hepatopulmonary syndrome; Hypertension pulmonary; Hypertension portal; Liver transplantation; Child

Fields of Study & Subjects

Pediatric Hepatobiliary Diseases and Treatments Liver Disease and Transplantation Congenital Heart Disease Studies

Publication details

Journal / source
Turkiye Klinikleri eBooks
Pages
211–225
Publication date
1 January 2026
Language
EN
Document type
Book chapter